BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8765431)

  • 1. Carboplatin pharmacokinetics in young children with brain tumors.
    Tonda ME; Heideman RL; Petros WP; Friedman HS; Murry DJ; Rodman JH
    Cancer Chemother Pharmacol; 1996; 38(5):395-400. PubMed ID: 8765431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
    Warren K; Gervais A; Aikin A; Egorin M; Balis FM
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors.
    Marina NM; Rodman J; Shema SJ; Bowman LC; Douglass E; Furman W; Santana VM; Hudson M; Wilimas J; Meyer W
    J Clin Oncol; 1993 Mar; 11(3):554-60. PubMed ID: 8445431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.
    Motzer RJ; Gulati SC; Tong WP; Menendez-Botet C; Lyn P; Mazumdar M; Vlamis V; Lin S; Bosl GJ
    Cancer Res; 1993 Aug; 53(16):3730-5. PubMed ID: 8393380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A clinical and pharmacokinetic study of high-dose carboplatin, paclitaxel, granulocyte colony-stimulating factor, and peripheral blood stem cells in patients with unresectable or metastatic cancer.
    Shea T; Graham M; Bernard S; Steagall A; Wiley J; Serody J; Brecher M; Bentley S; Johnston C; Vaisman A
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):80-5. PubMed ID: 7481867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors.
    Marina NM; Rodman JH; Murry DJ; Shema SJ; Bowman LC; Jones DP; Furman W; Meyer WH; Pratt CB
    J Natl Cancer Inst; 1994 Apr; 86(7):544-8. PubMed ID: 8133538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer Group.
    Cairo MS; Krailo MD; Weinthal JA; Secola R; Bergeron S; van de Ven C; Blazar BR; Garrison L; Reaman GH
    Cancer; 1998 Oct; 83(7):1449-60. PubMed ID: 9762948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma.
    Newell DR; Eeles RA; Gumbrell LA; Boxall FE; Horwich A; Calvert AH
    Cancer Chemother Pharmacol; 1989; 23(6):367-72. PubMed ID: 2469544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
    Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
    Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation.
    Rodman JH; Murry DJ; Madden T; Santana VM
    J Clin Oncol; 1994 Nov; 12(11):2390-7. PubMed ID: 7964955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy.
    de Jonge ME; Huitema AD; Tukker AC; van Dam SM; Rodenhuis S; Beijnen JH
    Clin Cancer Res; 2005 Jan; 11(1):273-83. PubMed ID: 15671556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue.
    Thorarinsdottir HK; Rood B; Kamani N; Lafond D; Perez-Albuerne E; Loechelt B; Packer RJ; MacDonald TJ
    Pediatr Blood Cancer; 2007 Mar; 48(3):278-84. PubMed ID: 16456857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of patients with recurrent medulloblastoma or central nervous system germinoma treated with low dose continuous intravenous etoposide along with dose-intensive chemotherapy followed by autologous hematopoietic stem cell rescue.
    Grodman H; Wolfe L; Kretschmar C
    Pediatr Blood Cancer; 2009 Jul; 53(1):33-6. PubMed ID: 19326417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions.
    Calvert AH; Boddy A; Bailey NP; Siddiqui N; Humphreys A; Hughes A; Robson L; Gumbrell L; Thomas H; Chapman F
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):91-8; discussion 99-100. PubMed ID: 7481870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary chemotherapy for intracranial germ cell tumors: results of the third international CNS germ cell tumor study.
    da Silva NS; Cappellano AM; Diez B; Cavalheiro S; Gardner S; Wisoff J; Kellie S; Parker R; Garvin J; Finlay J
    Pediatr Blood Cancer; 2010 Mar; 54(3):377-83. PubMed ID: 20063410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [High dose chemotherapy with thiotepa, carboplatin, VP16 and autologous stem cell transplantation in treatment of malignant brain tumors with poor prognosis. Results of a mono-center pilot study].
    Fleischhack G; Pöpping K; Hasan C; Utsch B; Jüttner J; Bode U
    Klin Padiatr; 1998; 210(4):248-55. PubMed ID: 9743961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin.
    De Jonge ME; Mathôt RA; Van Dam SM; Beijnen JH; Rodenhuis S
    Cancer Chemother Pharmacol; 2002 Sep; 50(3):251-5. PubMed ID: 12203108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A.
    Raschko JW; Synold TW; Chow W; Coluzzi P; Hamasaki V; Leong LA; Margolin KA; Morgan RJ; Shibata SI; Somlo G; Tetef ML; Yen Y; ter Veer A; Doroshow JH
    Cancer Chemother Pharmacol; 2000; 46(5):403-10. PubMed ID: 11127945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study.
    Porter D; Boddy A; Thomas H; Lind M; Newell D; Calvert AH; Robson L; Brampton M; Abrahamsen D; Winograd B
    Semin Oncol; 1996 Dec; 23(6 Suppl 13):34-44. PubMed ID: 8996574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support.
    van Warmerdam LJ; Rodenhuis S; van der Wall E; Maes RA; Beijnen JH
    Br J Cancer; 1996 Apr; 73(8):979-84. PubMed ID: 8611435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.